Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Jacobio Pharmaceuticals has announced that the U.S. FDA has approved their Investigational New Drug application for JAB-23E73, a drug aimed at treating cancer patients with KRAS mutations. The company plans to proceed with phase I/IIa clinical trials in the U.S. and awaits approval for trials in China. This announcement highlights Jacobio’s ongoing commitment to innovative cancer treatment solutions.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.